PMID- 30546466
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 16
IP  - 6
DP  - 2018 Dec
TI  - Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective 
      study.
PG  - 7271-7277
LID - 10.3892/ol.2018.9553 [doi]
AB  - Anaplastic thyroid cancer (ATC) is associated with an extremely poor prognosis 
      and is resistant to the majority of chemotherapies. In 2015, lenvatinib was 
      approved for treating ATC in Japan. The present study aimed to evaluate the 
      overall survival (OS) of patients with ATC treated with lenvatinib. A total of 23 
      patients with a definitive histological diagnosis of ATC who were treated at 
      Kanagawa Cancer Center (Yokohama, Kanagawa. Japan) were enrolled. Surgical 
      treatment was possible in 10 patients (including one debulking surgery), and 
      lenvatinib treatment was postoperatively started. The remaining 13 patients were 
      not eligible for debulking surgery; thus, lenvatinib was promptly approved as a 
      life-saving treatment. The therapeutic effect was determined according to the 
      Response Evaluation Criteria In Solid Tumors criteria (ver.1.1). The patients 
      exhibited a lenvatinib response rate of 17.4% and a disease control rate of 
      43.5%. However, lenvatinib was associated with a 100% incidence of 
      treatment-related adverse events (AEs), with hypertension being the most common 
      AE (91.3%). Additionally, dose interruptions and reductions were required due to 
      the development of tumor fistulas or other tumor-related AEs, and 9 (39.1%) 
      patients discontinued treatment due to grade 3 or higher AEs. The median OS time 
      was 166 days. Overall, the present study demonstrated the effectiveness of 
      lenvatinib against ATC, which is often chemotherapy-resistant. Successful 
      treatment of fistulas developing due to tumor necrosis at the site of the primary 
      lesion is crucial for improving the patient outcome. The response to lenvatinib 
      in patients with ATC varies on a case-by-case basis and requires further 
      investigation in future studies.
FAU - Iwasaki, Hiroyuki
AU  - Iwasaki H
AD  - Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, 
      Kanagawa 241-8515, Japan.
FAU - Yamazaki, Haruhiko
AU  - Yamazaki H
AD  - Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, 
      Kanagawa 241-8515, Japan.
FAU - Takasaki, Hirotaka
AU  - Takasaki H
AD  - Department of Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, 
      Japan.
FAU - Suganuma, Nobuyasu
AU  - Suganuma N
AD  - Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, 
      Kanagawa 241-8515, Japan.
FAU - Nakayama, Hirotaka
AU  - Nakayama H
AD  - Department of Surgical Treatment, Yokohama City University Hospital, Yokohama, 
      Kanagawa 236-0004, Japan.
FAU - Toda, Soji
AU  - Toda S
AD  - Department of Breast and Thyroid Surgery, Yokohama City University Medical 
      Center, Yokohama, Kanagawa 232-0024, Japan.
FAU - Masudo, Katsuhiko
AU  - Masudo K
AD  - Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, 
      Kanagawa 241-8515, Japan.
LA  - eng
PT  - Journal Article
DEP - 20181005
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC6256365
OTO - NOTNLM
OT  - anaplastic thyroid cancer
OT  - disease control rate
OT  - lenvatinib
OT  - overall survival
OT  - retrospective study
OT  - safety and efficacy
EDAT- 2018/12/14 06:00
MHDA- 2018/12/14 06:01
PMCR- 2018/10/05
CRDT- 2018/12/15 06:00
PHST- 2018/05/25 00:00 [received]
PHST- 2018/09/13 00:00 [accepted]
PHST- 2018/12/15 06:00 [entrez]
PHST- 2018/12/14 06:00 [pubmed]
PHST- 2018/12/14 06:01 [medline]
PHST- 2018/10/05 00:00 [pmc-release]
AID - OL-0-0-9553 [pii]
AID - 10.3892/ol.2018.9553 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 Dec;16(6):7271-7277. doi: 10.3892/ol.2018.9553. Epub 2018 Oct 5.